A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.

NCT07520565 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1112

Enrollment

INDUSTRY

Sponsor class

Conditions

AIS

Interventions

DRUG: BXOS110
DRUG: placebo

Sponsor

Biocells (Beijing) Biotech Co.,Ltd